Daily Nasal Sprays vs. Immunotherapy: What the Research Says About Long-Term Allergy Relief

Corticosteroid nasal sprays are the single most widely prescribed treatment for allergic rhinitis worldwide. They work, they're affordable, and for millions of patients they provide genuine day-to-day relief. But a growing body of research raises an important question: if you've been using a daily nasal spray for years and your allergies haven't improved — or have gotten worse — is the spray actually solving the problem, or just managing it?

The answer, according to multiple international allergy organizations, is clear. Nasal sprays manage symptoms. Only allergen immunotherapy modifies the underlying disease.

How Corticosteroid Nasal Sprays Work

Intranasal corticosteroids — the class that includes the most commonly used daily allergy sprays — work by binding to glucocorticoid receptors in the nasal mucosa. Once bound, they suppress the local release of inflammatory mediators including histamine, leukotrienes, and prostaglandins. They also reduce the recruitment of eosinophils and other inflammatory cells to the nasal tissue.¹

The result is a meaningful reduction in nasal congestion, rhinorrhea, sneezing, and itching. With consistent daily use, most patients notice improvement within a few days, with peak effectiveness at one to two weeks. For symptom control during active allergen exposure, corticosteroid nasal sprays are highly effective.

What they do not do is change allergen-specific IgE levels, alter immune memory, or reduce the sensitivity of mast cells to future allergen encounters. When you stop using the spray, the inflammatory response returns — often within days — because the underlying immune dysfunction remains exactly as it was.

How Antihistamine Nasal Sprays Differ

Antihistamine nasal sprays take a different approach. Rather than broadly suppressing inflammation, they block H1 receptors directly in the nasal tissue. This gives them a faster onset of action — many patients notice relief within 15 minutes, compared to hours or days for corticosteroids.²

However, the scope of their action is narrower. Histamine is only one of many mediators involved in the allergic cascade. Leukotrienes, prostaglandins, cytokines, and chemokines all contribute to the full allergic response, and H1 blockade alone does not address them. Like corticosteroids, antihistamine nasal sprays provide no disease-modifying effect. Symptoms return when treatment stops.

The Core Limitation Both Share

In 2020, the World Allergy Organization (WAO) published a comprehensive position paper on allergen immunotherapy that drew a clear line between symptom management and disease modification. The paper states explicitly that allergen immunotherapy is the only treatment class that modifies the underlying immune response driving allergic disease — shifting the immune system from an allergic Th2-dominant response toward a tolerogenic profile characterized by regulatory T cells and blocking IgG4 antibodies.³

Neither corticosteroid nor antihistamine nasal sprays produce this shift. They intervene downstream of the immune decision that causes the allergic response in the first place. This is why patients can use daily nasal sprays for five, ten, or twenty years and still need them every season — the immune system's posture toward the allergen has not changed.

"Allergen immunotherapy is the only treatment that targets the underlying allergic disease mechanism rather than just the symptoms. It is the only intervention with the potential to alter the natural course of allergic disease." — World Allergy Organization Position Paper, 2020

Long-Term IgE Data: Two Different Trajectories

A 2017 meta-analysis published in the Journal of Allergy and Clinical Immunology examined immune biomarker trajectories in patients receiving pharmacotherapy alone versus allergen immunotherapy. The findings illustrate two fundamentally different immune paths.⁴

Patients using intranasal corticosteroids for five or more years showed no significant reduction in allergen-specific IgE levels. Their immune systems continued to produce the same antibodies driving the allergic response, year after year. Symptom scores improved during active use but returned to baseline when treatment was paused or discontinued.

Immunotherapy patients showed a markedly different pattern: measurable increases in allergen-specific IgG4 (blocking antibodies that compete with IgE for allergen binding), gradual suppression of allergen-specific IgE, and expansion of regulatory T cell populations. These changes persisted after treatment ended — evidence of genuine immune remodeling rather than temporary suppression.

A Note on Preservatives and Long-Term Nasal Spray Use

Some nasal spray formulations contain benzalkonium chloride (BKC) as a preservative. Research by Roca-Ferrer et al. published in the Journal of Allergy and Clinical Immunology found that BKC exposure was associated with dose-dependent damage to nasal mucosal epithelial cells in vitro, including disruption of tight junctions and increased epithelial permeability.⁵

Not all nasal spray formulas contain BKC, and the clinical significance of these findings in real-world use remains a subject of ongoing study. However, for patients who have been on a daily nasal spray for years, it is worth checking the inactive ingredients and discussing preservative-free alternatives with a physician if BKC is present.

When Daily Nasal Sprays Are Still the Right Choice

None of this means nasal sprays are bad medicine. They remain an important tool in allergy management, and for certain patients and situations they are the most appropriate option:

• Acute seasonal flares: When pollen counts spike and a patient needs rapid symptom control, a corticosteroid or antihistamine spray provides immediate relief that immunotherapy — which works over months — cannot match in the moment.
• Bridge therapy: During the early months of immunotherapy, before tolerance has fully developed, nasal sprays can manage breakthrough symptoms effectively.
• Mild or occasional symptoms: Patients with infrequent, mild allergic rhinitis may not need or want the commitment of an immunotherapy course.
• Patients not candidates for immunotherapy: Certain medical conditions, including severe uncontrolled asthma, may make immunotherapy inappropriate. Nasal sprays remain a safe and effective alternative.

The question is not whether nasal sprays work — they clearly do. The question is whether symptom suppression alone is sufficient for patients whose allergies are persistent, worsening, or significantly affecting quality of life.

The Immunotherapy Difference

Three of the world's leading allergy organizations — the World Allergy Organization (WAO), the European Academy of Allergy and Clinical Immunology (EAACI), and the American Academy of Allergy, Asthma & Immunology (AAAAI) — all recognize sublingual immunotherapy as a disease-modifying treatment for allergic rhinitis.^3,6

What sets immunotherapy apart is a single, critical distinction: it is the only allergy treatment with evidence for sustained clinical tolerance after the treatment course ends. Patients who complete a full course of SLIT continue to show reduced symptoms and reduced medication use for years after stopping treatment. No nasal spray — corticosteroid or antihistamine — produces this effect.

For patients who have been managing allergies with a daily spray for years and find themselves wondering why things aren't getting better, this distinction is the answer. The spray is doing its job — suppressing symptoms. But it was never designed to resolve the underlying problem.